Join us for a virtual KOL event with Sensei Biotherapeutics, featuring James Gulley, M.D., Ph.D., FACP (National Cancer Institute), who will discuss the unmet medical need in solid tumors and the current immuno-oncology treatment landscape, along with the potential for Sensei’s lead candidate SNS-101 to improve treatment outcomes for patients.

Sensei Bio leadership will provide insight into the preclinical mechanism and profile of SNS-101, a conditionally active VISTA-blocking antibody, and present an overview of the SNS-101 clinical program, including collaborating with the National Cancer Institute as a clinical site for the Phase 1/2 SNS-101 clinical study.

A live question and answer session will follow the formal presentations.